

## DAFTAR PUSTAKA

1. Roth GA, Huffman MD, Moran AE, Feigin V, Mensah GA, Naghavi M, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. *Circulation*. 2015; 132: 1667-1678.
2. World Health Organization. The Top Ten Causes of Death. Diunduh dari <http://www.who.int/mediacentre/factsheets/fs310/en/>. 2018.
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. *Circulation*. 2016; 133: e38–e60.
4. RISKEDAS. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKEDAS). L Nas. 2018; 1-88.
5. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. ESC guidelines on the management of stable coronary artery disease. The task force on the management of stable coronary artery disease of the European Society of Cardiology. *European Heart Journal*. 2013;34:2949–3003
6. Fang L, Dart AM. Immune and inflammatory responses in subjects with stable angina and acute myocardial infarction. *Journal of Geriatric Cardiology*. 2015. 12: 202–203.
7. Munk PS, Breland UM, Aukrust P, Skadberg O, Ueland T, Larsen AI. Inflammatory response to percutaneous coronary intervention in stable coronary artery disease. *J Thromb Thrombolysis*. 2011; 31:92–98.
8. Gomes WJ, Buffolo E. Coronary stenting and Inflammation: implications for further surgical and medical treatment. *Ann Thorac Surg*. 2006; 81: 1918 – 1925.
9. Spertus JA, Maron DJ, Cohen DJ, Kolm P, Hartigan P, Weintraub WS, et al. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. *Circ Cardiovasc Qual Outcomes*. 2013; 6: 409-18.
10. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur J Cardiothorac Surg*. 2014; 46: 517–592.
11. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. *Circulation*. 2007;115:1051-1058.
12. Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status, and future directions, *Br. Med. Bull*. 2013; 106: 193–211.

13. Goto K, Zhao Z, Matsumura M, Dohi T, Kobayashi N, Kirtane AJ, et al. Mechanisms and patterns of intravascular ultrasound in-stent restenosis among bare metal stents and first- and second-generation drug-eluting stents. *Am. J. Cardiol.* 2015; 116: 1351–1357.
14. Welt FGP, Campbell R. Inflammation and restenosis in the stent era. *Arterioscler Thromb Vasc Biol.* 2002;22: 1769-1776.
15. Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. *F Thorac Dis* 2016; 8(10):E1150-E1162
16. Byrne RA, Sarafoff N, Kastrati A, Schomig A. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. *Drug Saf.* 2009; 32: 749–70.
17. Mohan S, Dhall A. A comparative study of restenosis rates in bare metal and drug-eluting stents. *Int J Angiol.* 2010; 19: e66-e72.
18. Holmes DR, Kereiakes DJ, Garg S, Serruys PW, Dehmer GJ, Ellis SG, et al. Stent thrombosis. *J. Am. Coll. Cardiol.* 2010 ;56: 1357–1365.
19. Lagerqvist B, Carlsson J, Frobert O, Lindbäck J, Scherstén FN, Stenestrand U, et al. Stent thrombosis in sweden : report from the Swedish Coronary Angiography and Angioplasty Registry. *Circ Cardiovasc Interv.* 2009; 2: 401-408.
20. Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 Patients. *JACC Cardiovasc Interv.* 2013; 6:1267-1274.
21. Navarese EP, Kowalewski M, Kandzari D, Lansky A, Górný B, Koltowski L, et al. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31,379 patients. *Open Heart* 1.2014; 1: e000064.
22. Chen W, Habraken TC, Hennink WE, Kok RJ. Polymer-free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents. *Bioconjug. Chem.* 2015; 26: 1277–1288.
23. Shitara J, Ogita M, Wada H, Tsuboi S, Endo H, Doi S, et al. Clinical impact of high-sensitivity C-reactive protein during follow-up on long-term adverse clinical outcomes in patients with coronary artery disease treated with percutaneous coronary intervention. *J Cardiol.* 2018: 1-6.
24. Gach O, Legrand V, Biessaux Y, Chapelle JP, Vanbelle S, Pierard LA. Long-term prognostic significance of high-sensitivity c-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. *Am J Cardiol.* 2007; 99: 31–35.
25. Saleh N, Tornvall P. Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is

associated with the risk of clinical restenosis. *Atherosclerosis*, 2007; 195: 374–378.

26. Du X, Kang JP, Wu JH, Lv Qiang, Tang CS, Ma CS. Elevated high sensitive C-reactive protein and apelin levels after percutaneous coronary intervention and drug-eluting stent implantation. *J Zhejiang Univ-Sci B*. 2010; 11(8): 548-552
27. Ribeiro D, Ramos A, Vieira P, Menti E, Bordin O, Souza P, et al. High-sensitivity C-reactive protein as a predictor of cardiovascular events after st-elevation myocardial infarction. *Arq Bras Cardiol*. 2014; 103(1):69-75.
28. Roubi SR, Pardal CB, Janeiro BR, Assi EA, Acunã J, Juanatey J. High-sensitivity C-reactive protein is a predictor of in-hospital cardiac events in acute myocardial infarction independently of GRACE risk score. *Angiology*. 2012; 63(1): 30-34.
29. Seyedian SM, Ahmadi F, Dabagh R, Davoodzadeh H. Relationship between high-sensitivity C-reactive protein serum levels and the severity of coronary artery stenosis in patients with coronary artery disease. *ARYA Atheroscler*. 2016; 12; 1-7.
30. Pan HC, Sheu WH, Lee WJ , Lee WL, Liao YC, Wang KY, et al. Coronary severity score and C-reactive protein predict major adverse cardiovascular events in patients with stable coronary artery disease (from the Taichung CAD study) *Clinica Chimica Acta*. 2015; 445: 93–100.
31. Razzouk L, Muntner P, Bansilal S, Kini AS, Aneja A, Mozes J, et al. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. *Am Heart J*. 2009; 158: 277–83.
32. Maejima N, Hibi K, Saka K, Akiyama E, Konishi M, Endo M, et al. Relationship between thickness of calcium on optical coherence tomography and crack formation after balloon dilatation in calcified plaque requiring rotational atherectomy. *Circ J*. 2016; 80: 1413 – 1419.
33. Schillinger M, Minar E. Restenosis after percutaneous angioplasty: the role of vascular inflammation. *Vascular Health and Risk Management*. 2005; 1: 73–78.
34. Sakr SA, Ramadan MM, El-Gamal A. The inflammatory response to percutaneous coronary intervention is related to the technique of stenting and not the type of stent. *The Egyptian Heart Journal*. 2016; 68: 37–43.
35. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. *Eur Heart J* 2004; 25: 1679 –1687.
36. Juni RP, Duckers HJ, Vanhoutte PM, Virmani R, MD, Moens AL. Oxidative stress and pathological changes after coronary artery interventions. *J Am Coll Cardiol* 2013; 61: 1471–1481.
37. Dores H, Raposo L, Teles RC, MachadoC, Leal S, Gonçalves PA, et al. Stent thrombosis with second- versus first-generation drug-eluting stents in real-world percutaneous coronary intervention: analysis of 3806 consecutive



procedures from a large-volume single-center prospective registry. *J. Invasive Cardiol.* 2013; 25: 330–336.

38. Tomberli B, Mattesini A, Baldereschi G, Mario CD. A Brief History of Coronary Artery Stents. *Rev Esp Cardiol.* 2018; 71: 312-319.
39. Slodownik D, Danenberg C, Merkin D, Swaid F, Moshe S, Ingber A, et al. Coronary stent restenosis and the association with allergy to metal content of 316L stainless steel. *Cardiovasc J Afr* 2018; 29: 43–45.
40. Kounis NG, Soufras GD. Coronary stent thrombosis: Beware of an allergic reaction and of Kounis syndrome. *Indian Heart Journal.* 2014; 66: 153-155.
41. Morgan KP, Kapur A, Beatt KJ. Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. *Heart.* 2004; 90: 732–738
42. Monraats PS, Pires N, Agema W, Zwinderman AH, Schepers A, Maat M. Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions. *Circulation.* 2005; 112: 2417-2425.
43. Popma J, Almonacid A, Burke D. Qualitative and quantitative coronary angiography. In : Topol EJ, Teristein PS, editors. *Textbook of international cardiology.* 6<sup>th</sup> ed. Philadelphia: Saunders Elsevier. 2012: 757-775.
44. Finch W, Lee MS. Percutaneous Coronary Intervention for Coronary Bifurcation Lesions. *Reviews in Cardiovascular Medicine.* 2017; 18 (2):59-66
45. Uretsky BF, Marashdeh M. Percutaneous coronary interventions of chronic total occlusions. In: Kern MJ, editor. *The interventional cardiac catheterization handbook.* 3<sup>rd</sup> ed. Philadelphia: Saunders Elsevier. 2013: 201-211.
46. Frobert O, Sarno G, James SK, Saleh N, Lagerqvist B. Effect of Stent Inflation Pressure and Post-Dilatation on the Outcome of Coronary Artery Intervention. A Report of More than 90 000 Stent Implantations. *PloS ONE.* 2013; 8(2): e56348.
47. Schmidt T, Abbott JD. Coronary Stents: History, Design, and Construction. *J. Clin. Med.* 2018; 7: 126-134.
48. Iqbal J, Gunn J, Serruys PW. Coronary stents: Historical development, current status and future directions. *Br. Med. Bull.* 2013; 106: 193–211.
49. Watson T, Webster MW, Ormiston JA, Ruygrok PN, Stewart JT. Long and short of optimal stent design. *Open Heart.* 2017; 4: e000680.
50. Choi JJ, Koh YS, Lim S, Kim JJ, Chang M, Kang M. Impact of the stent length on long-term clinical outcomes following newer-generation drug-eluting stent implantation. *Am J Cardiol.* 2014; 113(3):457-464.
51. Stone GW, Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Peruga JZ, et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI

- (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. *J Am Coll Cardiol*. 2010;56:1597-604.
52. Popma JJ, Tiroch K, Almonacid A, Cohen S, Kandzaki DE, Leon MB. A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation. *Am J Cardiol*. 2009; 103: 923-929.
53. Butany J, Carmichael K, Leong SW, Collins MJ. Coronary artery stents: identification and evaluation. *J Clin Pathol*. 2005; 58: 795–804.
54. Noad, R.L, Hanratty CG, Walsh S.J. Clinical impact of stent design. *Interv. Cardiol. Rev*. 2014, 9, 89–93.
55. Lee DH, Hernandez J. The newest generation of drug eluting stents and beyond. *European Cardiology Review*. 2018; 13(1): 54-59.
56. Conti M, Auricchio F, Denis VL, Beule MD. Impact of carotid stent cell design on vessel scaffolding: a case study comparing experimental investigation and numerical simulations. *Journal of Endovascular Therapy*. 18(3):397-406.
57. Lupi A, Schaffer A, Bongo AS. Should ultrathin strut drug eluting stents be considered the new benchmark for novel coronary stents approval? The complex interplay between stent strut thickness, polymeric carriers and antiproliferative drugs. *Thorac Dis* 2018;10(2):678-681
58. Foin N, Barrero EA, Sen S, Petraco R. Maximal expansion capacity with current des platforms: a critical factor for stent selection in the treatment of left main bifurcations? *EuroIntervention*. 2013; 8: 1315-1325.
59. Mori H, Gupta A, Torii S, et al. Clinical implications of blood material interaction and drug eluting stent polymers in review. *Expert Rev Med Devices* 2017;14:707–16.
60. Strohbach A, Busch R. Polymer for cardiovascular stent coatings. *International Journal of Polymer Science*. 2015: 1-12.
61. Urban P, Meredith IT, Abizaid A, Pocock SJ, LEADERS FREE Investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk. *N Engl J Med*. 2015;373:2038–2047.
62. Baquet M, Jochheim D, Mehilli J. Polymer-free drug-eluting stents for coronary artery disease. *J Interven Cardiol*. 2018; 31: 330–337.
63. Thakkar AS, Dave BA. Revolution of drug-eluting coronary stents: an analysis of market leaders. *EMJ*. 2016;1(4):114-125.
64. Ernst A, Bulum J. New generations of drug eluting stents: a brief review. *European Medical Journal*. 2014; 7: 100-107
65. Zbinden R, Felten SV, Wein B, Tueller D, Kurz DJ, Reho I. Impact of stent diameter and length on in- stent restenosis after DES vs BMS implantation in patients needing large coronary stents—A clinical and health- economic evaluation. *Cardiovascular Therapeutics*. 2017; 35: 19–25.
66. Chitkara K, Gershlick A. Second versus first generation drug eluting stents. *International Cardiology Review*. 2010; 5(1):23-26.

67. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskin O, Schomig A, et al. Durability of antirestenotic efficacy in drug eluting stents with and without permanent polymer. *JACC Cardiovasc. Interv.* 2009; 2: 291-299.
68. Kim JS, Kim JH, Shin DH, Kim BK, Ko YG, Choi D. Effect of high-dose statin therapy on drug-eluting stent strut coverage. *Arterioscler Thromb Vasc Biol.* 2015; 35: 2460-2467.
69. Adukauskienė D, Čiginskienė A, Adukauskaitė A, Pentiokinienė D, Šlapikas R, Čeponienė I. Clinical relevance of high sensitivity C-reactive protein in cardiology. *Medicina.* 2016; 52: 1-10.
70. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. *Int J Cardiol.* 2013; 168(6): 5126–5134.
71. Salazar J, Martinez MS, Mervin Chavez M, Toledo A, Anez R, Yaquelín Torres Y, et al. C-reactive protein: clinical and epidemiological perspectives. *Cardiology Research and Practice.* 2014;2014:1-10.
72. Silva D, Pais de Lacerda A. High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease. *Rev Port Cardiol.* 2012; 31(11): 733–45.
73. Gaspardone A, Versaci F. Coronary stenting and inflammation. *Am J Cardiol* 2005;96[suppl]:65L–70L.
74. Almagor M, Keren A, Banai S. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. *Am Heart J.* 2003;145:248 –253.
75. Bendary A, Wagdy B, Azm TA, Sanad O. Elevated high-sensitivity C-reactive protein after percutaneous coronary intervention in patients with stable coronary artery disease: a proof-of-concept study. *Res Cardiovasc Med.* 2018;7:130-136.
76. Delhay C, Sudre A, Lemesle G, Marechaux S, Brouqsault D, Hennache B, et al. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. *Cardiovasc Revasc Med.* 2009; 10: 144–150.
77. Alyavi AL, Alyavi BA, Tulyaganova DK, Aliahunova MY, Sabirzhanova ZT, Nuritdinova SK. Features of inflammatory markers in patients with coronary heart disease. *International Journal of Healthcare and Medical Sciences.* 2018; 4 (10): 188-192.
78. Ozyuncu N, Gulec S, Ozcan OU, Goksuluk H, Gerede DM, Caglar N, et al. Comparison of the Effects of Bare Metal Stents and Drug Eluting Stents on C-Reactive Protein Levels. *J Heart Cardiol.* 2015; 1 : 44-50.
79. Kang WC, Ahn TH, Moon CI, Han SH, Shin EK. Impact of arterial remodeling on high sensitive C-reactive protein after DES implantation. *Int J Cardiol.* 2010; 145(2): 325-326.



80. Kang WC, Moon CI, Lee L, Han SH, Suh SY, Moon J, et al. Comparison of inflammatory markers for the prediction of neointimal hyperplasia after drug-eluting stent implantation. *Coronary Artery Disease*. 2011; 22: 526–532.
81. Windecker S, O’Sullivan CJ. Mitigating the Risk of Early Stent Thrombosis. *JACC*. 2014; 63 (23): 2521–2424.
82. Zhu X, Chen Y, Xiang L, You T, Jiao Y, Xu W, et al. The long-term prognostic significance of high-sensitive C-reactive protein to in-stent restenosis. *Medicine*. 2018; 97:27-33.
83. Gerbay A, Terreaux J, Cerisier A, Vola M, Isaz Karl. Impact of very high pressure stent deployment on angiographic and long-term clinical outcomes in true coronary bifurcation lesions treated by the mini-crush stent technique: A single center experience. *Indian Heart J*. 2017 Jan-Feb; 69(1): 32–36.
84. Nour MK. Impact of stent deployment pressure and poststenting dilatation on the outcome of elective percutaneous coronary intervention. *Research Reports in Clinical Cardiology* 2016;7 :109–116.
85. Morton AC, Arnold ND, Crossman DC, Gunn J. Response of very small (2 mm) porcine coronary arteries to balloon angioplasty and stent implantation. *Heart*. 2004; 90(3): 324–327.
86. Brancati MF, Burzotta F, Trani C, Leonzi O, Cuccia C, Crea F. Coronary stents and vascular response to implantation: literature review. *Pragmatic and Observational Research*. 2017;8 137–141.
87. Adnan Y, Noor L, Dar MH, Ali U, Hafizullah M. Impact of stent length and diameter on short term clinical outcomes of drug eluting stents in patients with stable coronary artery disease. *Pak J Med Sci*. 2017 Jul-Aug; 33(4): 959–962.
88. Xu B, Saito Y, Baumbach A, Kelbæk H, Royen NV, Zheng M, et al. 2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. *JACC*. 2019; 12 (17): 1679-1687.

